ADVFN - Advanced Financial Network.
HOME» NASDAQ » A » AMGN Stock Price » AMGN Stock News

Amgen Inc. Share News

 Amgen Inc. (mm) Stock Price
AMGN Stock Price
 Amgen Inc. (mm) Stock Chart
AMGN Stock Chart
 Amgen Inc. (mm) Stock News
AMGN Stock News
 Amgen Inc. (mm) Company Information
AMGN Company Information
 Amgen Inc. (mm) Stock Trades
AMGN Stock Trades

Amgen Says Recent Sensipar Study Failed to Meet Primary Endpoint

By Mia Lamar Amgen Inc. (AMGN) said Friday that a study evaluating its Sensipar drug for effectiveness in reducing the risk of mortality and cardiovascular events in patients suffering from chronic kidney disease failed to meet its primary endpoint. Sensipar--which is marketed as Mimpara in Europe--was first approved in 2004 to treat thyroid problems in patients with kidney disease and cancer. The company recorded $808 million in global sales of the drug last year. Amgen said Friday it undertook the Phase 3 trial of Sensipar to discover whether the drug could positively impact the high rates of mortality and incidences like heart failure experienced by patients with chronic kidney disease that are receiving dialysis. Results, however, were not statistically significant, Amgen said. The company noted analyses from the study are ongoing and will be submitted for presentation at a major medical meeting later this year. Amgen, the biggest stand-alone biotechnology company, has been pursuing deals to bolster its research-and-development pipeline as sales growth slows for older drugs. Shares were recently off 26 cents to $68.84. Write to Mia Lamar at mia.lamar@dowjones.com

Stock News for Amgen Inc. (AMGN)
DateTimeHeadline
05/27/201607:21:00Amgen Receives Positive CHMP Opinion To Extend Indication Of...
05/26/201616:00:00Kyprolis® (Carfilzomib) Demonstrates Economic Value In Relapsed...
05/26/201606:10:34Current Report Filing (8-k)
05/25/201619:08:00Amgen Announces Early Tender Results Of Senior Notes Exchange...
05/25/201616:09:00Amgen Announces Pricing Terms Of Senior Notes Exchange Offers
05/23/201616:40:00Samsung Targets U.S. Drug Market With Remicade Knockoff
05/19/201618:02:00Amgen Announces Voting Results of Annual Meeting of Stockholders
05/19/201616:34:00Amgen Highlights Data To Be Presented At 21st Congress Of The...
05/18/201617:44:00Amgen Researchers Discover Gene Associated With Lower Risk of...
05/18/201617:06:00Bayer to Showcase Latest Oncology Research at ASCO 2016
05/18/201617:05:00Amgen Data To Be Presented At ASCO 2016 Demonstrates More Insights...
05/18/201617:00:00Landmark deCODE genetics Study Points to a New Mechanism that...
05/17/201616:00:00Amgen's Breakaway from Cancer® Public Service Announcement Delivers...
05/13/201606:16:35Current Report Filing (8-k)
05/12/201621:14:00Amgen Commences Exchange Offers for Certain Series of Outstanding...
05/12/201603:03:00Theranos Executive to Exit Amid Probes -- WSJ
05/11/201623:10:00Theranos Executive Sunny Balwani to Depart Amid Regulatory Probes
05/11/201622:15:00Theranos Executive Sunny Balwani to Depart Amid Regulatory Probes
05/11/201622:10:00Theranos Executive Sunny Balwani to Depart
05/11/201621:49:00Theranos Executive Sunny Balwani to Depart Amid Regulatory Probes

Amgen Inc. and other NASDAQ stock quotes are delayed by at least 20 minutes.
All other stock price and quote data is delayed by at least 15 minutes unless otherwise stated. By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Contact Us | Copyright 1999-2015 ADVFN PLC. | Privacy Policy | Investment Warning | Data accreditations | Investor Relations

ADVFNADVFN ItalyADVFN GermanyADVFN FranceADVFN BrazilADVFN JapanADVFN UKADVFN US noad